Literature DB >> 11579071

Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction.

S D Anderson1, G J Argyros, H Magnussen, K Holzer.   

Abstract

The International Olympic Committee Medical Commission (IOC-MC) requires notification for use of a beta(2) agonist at the Winter Olympic Games in Salt Lake City. This notification will be required seven days before the event and must be accompanied by objective evidence that justifies the need to use one. The IOC-MC has expressed the viewpoint that, at present, eucapnic voluntary hyperpnoea (EVH) is the optimal laboratory challenge to confirm that an athlete has exercise induced bronchoconstriction (EIB). The EVH test recommended was specifically designed to identify EIB. EVH has been performed in thousands of subjects in both the laboratory and the field. The test requires the subject to hyperventilate dry air containing 5% carbon dioxide at room temperature for six minutes at a target ventilation of 30 times the subject's forced expiratory volume in one second (FEV(1)). The test conditions can be modified to simulate the conditions that give the athlete their symptoms with exercise. A reduction in FEV(1) of 10% or more of the value before the test is considered positive.

Entities:  

Mesh:

Year:  2001        PMID: 11579071      PMCID: PMC1724385          DOI: 10.1136/bjsm.35.5.344

Source DB:  PubMed          Journal:  Br J Sports Med        ISSN: 0306-3674            Impact factor:   13.800


  26 in total

1.  Sensitivity and specificity of bronchial provocation testing. An evaluation of four techniques in exercise-induced bronchospasm.

Authors:  A H Eliasson; Y Y Phillips; K R Rajagopal; R S Howard
Journal:  Chest       Date:  1992-08       Impact factor: 9.410

2.  The relative contributions of histamine and prostanoids to bronchoconstriction provoked by isocapnic hyperventilation in asthma.

Authors:  J P Finnerty; A Harvey; S T Holgate
Journal:  Eur Respir J       Date:  1992-03       Impact factor: 16.671

3.  Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma.

Authors:  J D Brannan; H Koskela; S D Anderson; N Chew
Journal:  Am J Respir Crit Care Med       Date:  1998-10       Impact factor: 21.405

4.  Cold air test: a simplified standard method for airway reactivity.

Authors:  B K Assoufi; M B Dally; A J Newman-Taylor; D M Denison
Journal:  Bull Eur Physiopathol Respir       Date:  1986 Jul-Aug

5.  Reactivity to cold-air hyperventilation in normal and in asthmatic children in a survey of 5,697 schoolchildren in southern Bavaria.

Authors:  T Nicolai; E V Mutius; P Reitmeir; M Wjst
Journal:  Am Rev Respir Dis       Date:  1993-03

6.  Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma.

Authors:  A S Vathenen; A J Knox; A Wisniewski; A E Tattersfield
Journal:  Thorax       Date:  1991-11       Impact factor: 9.139

7.  Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma.

Authors:  K M Hurwitz; G J Argyros; J M Roach; A H Eliasson; Y Y Phillips
Journal:  Chest       Date:  1995-11       Impact factor: 9.410

8.  Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours.

Authors:  D Nowak; R Jörres; K F Rabe; M Lüthke; J Wiessmann; H Magnussen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Eucapnic voluntary hyperventilation as a bronchoprovocation technique. Comparison with methacholine inhalation in asthmatics.

Authors:  J M Roach; K M Hurwitz; G J Argyros; A H Eliasson; Y Y Phillips
Journal:  Chest       Date:  1994-03       Impact factor: 9.410

10.  The refractory period after eucapnic voluntary hyperventilation challenge and its effect on challenge technique.

Authors:  G J Argyros; J M Roach; K M Hurwitz; A H Eliasson; Y Y Phillips
Journal:  Chest       Date:  1995-08       Impact factor: 9.410

View more
  47 in total

Review 1.  Exercise-induced bronchospasm in the elite athlete.

Authors:  Kenneth W Rundell; David M Jenkinson
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

2.  Screening for exercise-induced bronchoconstriction in college athletes.

Authors:  Jonathan P Parsons; David Cosmar; Gary Phillips; Christopher Kaeding; Thomas M Best; John G Mastronarde
Journal:  J Asthma       Date:  2012-01-25       Impact factor: 2.515

3.  Mid-expiratory flow versus FEV1 measurements in the diagnosis of exercise induced asthma in elite athletes.

Authors:  J W Dickinson; G P Whyte; A K McConnell; A M Nevill; M G Harries
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

Review 4.  Making the diagnosis of asthma in the athlete.

Authors:  Chris Randolph
Journal:  Clin Rev Allergy Immunol       Date:  2005-10       Impact factor: 8.667

5.  Screening elite winter athletes for exercise induced asthma: a comparison of three challenge methods.

Authors:  J W Dickinson; G P Whyte; A K McConnell; M G Harries
Journal:  Br J Sports Med       Date:  2006-02       Impact factor: 13.800

Review 6.  Diagnostic and therapeutic value of airway challenges in asthma.

Authors:  Donald W Cockcroft; Beth E Davis
Journal:  Curr Allergy Asthma Rep       Date:  2009-05       Impact factor: 4.806

7.  Bronchoprovocation testing.

Authors:  Chakravarthy Reddy
Journal:  Clin Rev Allergy Immunol       Date:  2009-03-17       Impact factor: 8.667

8.  Impact of changes in the IOC-MC asthma criteria: a British perspective.

Authors:  J W Dickinson; G P Whyte; A K McConnell; M G Harries
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

Review 9.  Diagnosis of asthma in adults.

Authors:  Alan G Kaplan; Meyer S Balter; Alan D Bell; Harold Kim; R Andrew McIvor
Journal:  CMAJ       Date:  2009-09-21       Impact factor: 8.262

Review 10.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.